Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia

Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?

Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782 · see citing works

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Ackermann, M., Verleden, S. E., Kuehnel, M., Haverich, A., Welte, T., Laenger, F., Vanstapel, A., Werlein, C., Stark, H., Tzankov, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015432 · Cited by 5,613 · see citing works

HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia

Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905 · see citing works

Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention

Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., et al. (2003) · Circulation · doi:10.1161/01.cir.0000095676.90936.80 · Cited by 3,768 · see citing works

Mitochondrial TCA cycle metabolites control physiology and disease

Martínez-Reyes, I., & Chandel, N. S. (2020) · Nature Communications · doi:10.1038/s41467-019-13668-3 · Cited by 2,813 · see citing works

HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption

Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267 · see citing works

Oxygen sensing by HIF hydroxylases

Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068 · see citing works

Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality

London, G. M. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg414 · Cited by 1,849 · see citing works

α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming

Liu, P.-S., Wang, H., Li, X., Chao, T., Teav, T., Christen, S., Di Conza, G., Cheng, W.-C., Chou, C.-H., Vavakova, M., et al. (2017) · Nature Immunology · doi:10.1038/ni.3796 · Cited by 1,264 · see citing works

Integration of Oxygen Signaling at the Consensus HRE

Wenger, R. H., Stiehl, D. P., & Camenisch, G. (2005) · Science's STKE · doi:10.1126/stke.3062005re12 · Cited by 1,032 · see citing works

Arterial stiffening and vascular calcifications in end‐stage renal disease

Guérin, A. P., London, G. M., Marchais, S. J., & Métivier, F. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.7.1014 · Cited by 996 · see citing works

Tissue Factor

Grover, S. P., & Mackman, N. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309846 · Cited by 672 · see citing works

Vascular Calcification

Mizobuchi, M., Towler, D. A., & Slatopolsky, E. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008070692 · Cited by 542 · see citing works

Regulation of iron transport and the role of transferrin

Gkouvatsos, K., Papanikolaou, G., & Pantopoulos, K. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.10.013 · Cited by 518 · see citing works

Energy metabolism in heart failure

Ventura‐Clapier, R., Garnier, A., & Veksler, V. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.055095 · Cited by 499 · see citing works

Expanding chemical biology of 2-oxoglutarate oxygenases

Loenarz, C., & Schofield, C. J. (2008) · Nature Chemical Biology · doi:10.1038/nchembio0308-152 · Cited by 498 · see citing works

Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism

Aragonés, J., Schneider, M. A., Geyte, K. V., Fraisl, P., Dresselaers, T., Mazzone, M., Dirkx, R., Zacchigna, S., Lemieux, H., Jeoung, N. H., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.62 · Cited by 472 · see citing works

Energy metabolism in heart failure and remodelling

Ingwall, J. S. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn301 · Cited by 462 · see citing works

Thrombosis and platelets: an update

Koupenova, M., Kehrel, B. E., Corkrey, H. A., & Freedman, J. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw550 · Cited by 462 · see citing works

Role of mitochondrial DNA in toxic responses to oxidative stress

Houten, B. V., Woshner, V. M., & Santos, J. H. (2005) · DNA repair · doi:10.1016/j.dnarep.2005.03.002 · Cited by 455 · see citing works

The stimulation of thrombosis by hypoxia

Gupta, N., Zhao, Y., & Evans, C. E. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.07.013 · Cited by 438 · see citing works

Alpha-Ketoglutarate, an Endogenous Metabolite, Extends Lifespan and Compresses Morbidity in Aging Mice

Shahmirzadi, A. A., Edgar, D., Liao, C., Hsu, Y.-M., Lucanic, M., Shahmirzadi, A. A., Wiley, C. D., Gan, G., Kim, D. E., Kasler, H. G., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.08.004 · Cited by 417 · see citing works

Hypoxia-Inducible Factor 1-Alpha Reduces Infarction and Attenuates Progression of Cardiac Dysfunction After Myocardial Infarction in the Mouse

Kido, M., Du, L., Sullivan, C. C., Li, X., Deutsch, R., Jamieson, S. W., & Thistlethwaite, P. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.045 · Cited by 331 · see citing works

Hypoxia-inducible factors in the kidney

Haase, V. H. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00071.2006 · Cited by 329 · see citing works

Mechanisms of hypoxia signalling: new implications for nephrology

Schödel, J., & Ratcliffe, P. J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0182-z · Cited by 309 · cited 1× · see citing works

Sequence determinants in hypoxia-inducible factor-1α for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3

Huang, J., Zhao, Q., Mooney, S. M., & Lee, F. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206955200 · Cited by 307 · see citing works

Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

Provenzano, R., Besarab, A., Sun, C. H., Diamond, S. A., Durham, J. H., Cangiano, J. L., Aiello, J. R., Novak, J. E., Lee, T. T., Leong, R., et al. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06890615 · Cited by 295 · see citing works

Preconditional Activation of Hypoxia-Inducible Factors Ameliorates Ischemic Acute Renal Failure

Bernhardt, W. M., Accent]mpean, V. C. C., Kany, S., Diaeresis]rgensen, J.-S. J., Weidemann, A., Warnecke, C., Arend, M., Klaus, S. J., Diaeresis]nzler, V. G., Amann, K., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121302 · Cited by 294 · see citing works

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

Besarab, A., Provenzano, R., Hertel, J., Zabaneh, R. I., Klaus, S. J., Lee, T. T., Leong, R., Hemmerich, S., Yu, K.-H. P., & Neff, T. B. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv302 · Cited by 289 · see citing works

Structural studies on human 2-oxoglutarate dependent oxygenases

McDonough, M. A., Loenarz, C., Chowdhury, R., Clifton, I. J., & Schofield, C. J. (2010) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2010.08.006 · Cited by 280 · see citing works

Physiological and biochemical aspects of hydroxylations and demethylations catalyzed by human 2-oxoglutarate oxygenases

Loenarz, C., & Schofield, C. J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.07.002 · Cited by 274 · see citing works

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study

Provenzano, R., Besarab, A., Wright, S., Dua, S., Zeig, S., Nguyen, P., Poole, L., Saikali, K. G., Saha, G. C., Hemmerich, S., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.12.020 · Cited by 265 · see citing works

Alpha-ketoglutarate ameliorates age-related osteoporosis via regulating histone methylations

Wang, Y., Deng, P., Liu, Y., Wu, Y., Chen, Y., Guo, Y., Zhang, S., Zheng, X., Zhou, L., Liu, W., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19360-1 · Cited by 259 · see citing works

Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis

Singh, A. K., Carroll, K., Perkovic, V., Solomon, S. D., Jha, V., Johansen, K. L., Lópes, R. D., Macdougall, I. C., Obrador, G. T., Waikar, S. S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113379 · Cited by 254 · see citing works

Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials

Yeh, T., Leissing, T. M., Abboud, M. I., Thinnes, C. C., Atasoylu, O., Holt‐Martyn, J. P., Zhang, D., Tumber, A., Lippl, K., Lohans, C. T., et al. (2017) · Chemical Science · doi:10.1039/c7sc02103h · Cited by 244 · see citing works

Impaired platelet responses to thrombin and collagen in AKT-1–deficient mice

Chen, J., De, S., Damron, D. S., Chen, W. S., Hay, N., & Byzova, T. V. (2004) · Blood · doi:10.1182/blood-2003-10-3428 · Cited by 238 · see citing works

Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis

Singh, A. K., Carroll, K., McMurray, J. J. V., Solomon, S. D., Jha, V., Johansen, K. L., Lópes, R. D., Macdougall, I. C., Obrador, G. T., Waikar, S. S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113380 · Cited by 234 · see citing works

Alpha-Ketoglutarate as a Molecule with Pleiotropic Activity: Well-Known and Novel Possibilities of Therapeutic Use

Zdzisińska, B., Żurek, A., & Kandefer-Szerszeń, M. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0406-x · Cited by 221 · see citing works

Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease

Haase, V. H. (2021) · Kidney International Supplements · doi:10.1016/j.kisu.2020.12.002 · Cited by 203 · see citing works

Metabolic remodelling of the failing heart: beneficial or detrimental?

van Bilsen, M., van Nieuwenhoven, F. A., & Vusse, G. J. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn282 · Cited by 191 · see citing works

Regulation of mitochondrial proliferation in the heart: power-plant failure contributes to cardiac failure in hypertrophy

Goffart, S., VONKLEISTRETZOW, J., & Wiesner, R. H. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.06.030 · Cited by 176 · see citing works

HIF Hydroxylase Pathways in Cardiovascular Physiology and Medicine

Bishop, T., & Ratcliffe, P. J. (2015) · Circulation Research · doi:10.1161/circresaha.117.305109 · Cited by 169 · see citing works

Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy

Moslehi, J. J., Minamishima, Y. A., Shi, J., Neuberg, D. S., Charytan, D. M., Padera, R. F., Signoretti, S., Liao, R., & Kaelin, W. G. (2010) · Circulation · doi:10.1161/circulationaha.109.922427 · Cited by 168 · see citing works

Alpha-ketoglutarate extends Drosophila lifespan by inhibiting mTOR and activating AMPK

Su, Y., Wang, T., Wu, N., Li, D., Fan, X., Xu, Z., Mishra, S. K., & Yang, M. (2019) · Aging · doi:10.18632/aging.102045 · Cited by 165 · see citing works

HIF‐prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism

Haase, V. H. (2017) · Hemodialysis International · doi:10.1111/hdi.12567 · Cited by 161 · see citing works

Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Ku, E., Vecchio, L. D., Eckardt, K., Haase, V. H., Johansen, K. L., Nangaku, M., Tangri, N., Waikar, S. S., Więcek, A., Cheung, M., et al. (2023) · Kidney International · doi:10.1016/j.kint.2023.05.009 · Cited by 156 · see citing works

Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor–1

Fink, T., Kazlauskas, A., Poellinger, L., Ebbesen, P., & Zachar, V. (2002) · Blood · doi:10.1182/blood.v99.6.2077 · Cited by 151 · see citing works

The role of Akt in the signaling pathway of the glycoprotein Ib-IX–induced platelet activation

Yin, H. X., Stojanović, A., Hay, N., & Du, X. (2007) · Blood · doi:10.1182/blood-2007-04-085514 · Cited by 145 · see citing works

Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcification

Mokas, S., Larivière, R., Lamalice, L., Gobeil, S., Cornfield, D. N., Agharazii, M., & Richard, D. E. (2016) · Kidney International · doi:10.1016/j.kint.2016.05.020 · Cited by 141 · see citing works

Akt signaling in platelets and thrombosis

Woulfe, D. S. (2010) · Expert Review of Hematology · doi:10.1586/ehm.09.75 · Cited by 138 · see citing works

Pharmacological targeting of the HIF hydroxylases – A new field in medicine development

Chan, M. C., Holt‐Martyn, J. P., Schofield, C. J., & Ratcliffe, P. J. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.01.001 · Cited by 126 · see citing works

Alpha-ketoglutarate ameliorates pressure overload-induced chronic cardiac dysfunction in mice

An, D., Zeng, Q., Zhang, P., Ma, Z., Zhang, H., Liu, Z., Li, J., Ren, H., & Xu, D. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102088 · Cited by 126 · see citing works

Molecular regulation of the PAI‐1 gene by hypoxia: contributions of Egr‐1, HIF‐1 α, and C/EBPα

Liao, H., Hyman, M. C., Lawrence, D. A., & Pinsky, D. J. (2006) · The FASEB Journal · doi:10.1096/fj.06-6285com · Cited by 118 · see citing works

Hypoxia Triggers Osteochondrogenic Differentiation of Vascular Smooth Muscle Cells in an HIF-1 (Hypoxia-Inducible Factor 1)–Dependent and Reactive Oxygen Species–Dependent Manner

Balogh, E., Tóth, A., Méhes, G., Trencsényi, G., Paragh, G., & Jeney, V. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312509 · Cited by 116 · see citing works

Anemia of chronic disorders: new diagnostic tools and new treatment strategies

Weiss, G. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.07.004 · Cited by 116 · see citing works

Pleiotropic effects of alpha-ketoglutarate as a potential anti-ageing agent

Bayliak, M. M., & Lushchak, V. I. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101237 · Cited by 115 · see citing works

The role of cardiac energy metabolism in cardiac hypertrophy and failure

Tuomainen, T., & Tavi, P. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.03.052 · Cited by 104 · see citing works

The multifaceted contribution of α-ketoglutarate to tumor progression: An opportunity to exploit?

Abla, H., Sollazzo, M., Gasparre, G., Iommarini, L., & Porcelli, A. M. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.031 · Cited by 96 · see citing works

Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors

Volke, M., Gale, D. P., Maegdefrau, U., Schley, G., Klanke, B., Bosserhoff, A.-K., Maxwell, P. H., Eckardt, K.-U., & Warnecke, C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007875 · Cited by 93 · see citing works

Metabolism—the lost child of cardiology∗∗Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Taegtmeyer, H. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00870-6 · Cited by 85 · see citing works

Hypoxia-Inducible Factor 1 and Mitochondria: An Intimate Connection

Huang, X., Zhao, L., & Peng, R. (2022) · Biomolecules · doi:10.3390/biom13010050 · Cited by 85 · see citing works

Hypoxia and low temperature upregulate transferrin to induce hypercoagulability at high altitude

Li, M., Tang, X., Liao, Z., Shen, C., Cheng, R., Fang, M., Gan, W., Li, Y., Tang, S., Xie, L., et al. (2022) · Blood · doi:10.1182/blood.2022016410 · Cited by 77 · see citing works

α-Ketoglutarate improves cardiac insufficiency through NAD+-SIRT1 signaling-mediated mitophagy and ferroptosis in pressure overload-induced mice

Yu, H., Gan, D., Luo, Z., Yang, Q., An, D., Zhang, H., Hu, Y., Ma, Z., Zeng, Q., Xu, D., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00783-1 · Cited by 75 · see citing works

Regulation of Erythropoiesis by the Hypoxia-Inducible Factor Pathway: Effects of Genetic and Pharmacological Perturbations

Semenza, G. L. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-102602 · Cited by 74 · see citing works

Stabilization of Hypoxia Inducible Factor Rather than Modulation of Collagen Metabolism Improves Cardiac Function After Acute Myocardial Infarction in Rats

Philipp, S., Jürgensen, J. S., Fielitz, J., Bernhardt, W. M., Weidemann, A., Schiche, A., Pilz, B., Dietz, R., Regitz‐Zagrosek, V., Eckardt, K., et al. (2006) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.10.009 · Cited by 70 · see citing works

Anaemia in CKD—treatment standard

Macdougall, I. C. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad250 · Cited by 60 · see citing works

Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors

Locatelli, F., Minutolo, R., Nicola, L. D., & Vecchio, L. D. (2022) · Drugs · doi:10.1007/s40265-022-01783-3 · Cited by 53 · see citing works

Cardiovascular Event Rates Among Hemodialysis Patients Across Geographical Regions—A Snapshot From The Dialysis Outcomes and Practice Patterns Study (DOPPS)

Stirnadel-Farrant, H. A., Karaboyas, A., Čižman, B., Bieber, B. A., Kler, L., Jones, D., Cobitz, A. R., & Robinson, B. M. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2019.03.016 · Cited by 53 · see citing works

Desidustat: First Approval

Dhillon, S. (2022) · Drugs · doi:10.1007/s40265-022-01744-w · Cited by 51 · see citing works

α-Ketoglutarate Inhibits Thrombosis and Inflammation by Prolyl Hydroxylase-2 Mediated Inactivation of Phospho-Akt

Shrimali, N. M., Agarwal, S., Kaur, S., Bhattacharya, S., Bhattacharyya, S., Prchal, J. T., & Guchhait, P. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103672 · Cited by 45 · see citing works

Role of oxygen and the HIF-pathway in polycystic kidney disease

Buchholz, B., & Eckardt, K. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109524 · Cited by 42 · see citing works

Human 2-oxoglutarate-dependent oxygenases: nutrient sensors, stress responders, and disease mediators

Fletcher, S. C., & Coleman, M. L. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190333 · Cited by 42 · see citing works

EPAS1/HIF-2 alpha-mediated downregulation of tissue factor pathway inhibitor leads to a pro-thrombotic potential in endothelial cells

Stavik, B., Espada, S., Cui, X., Iversen, N., Holm, S., Mowinckel, M., Halvorsen, B. L., Skretting, G., & Sandset, P. M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.01.017 · Cited by 42 · see citing works

Targeting mitochondrial dysfunction in the treatment of heart failure

Sabbah, H. N. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1249466 · Cited by 34 · see citing works

Regulation of the 2-oxoglutarate-dependent dioxygenases and implications for cancer

Vissers, M. C. M., Kuiper, C., & Dachs, G. U. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140118 · Cited by 32 · see citing works

Daprodustat Accelerates High Phosphate-Induced Calcification Through the Activation of HIF-1 Signaling

Tóth, A., Csiki, D. M., Nagy, B., Balogh, E., Lente, G., Ababneh, H., Szöőr, Á., & Jeney, V. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.798053 · Cited by 32 · see citing works

Hypoxia-Inducible Factor 1-Alpha and Glucose Metabolism during Cardiac Remodeling Progression from Hypertrophy to Heart Failure

Sant’Ana, P. G., de Tomasi, L. C., Murata, G. M., Vileigas, D. F., Mota, G. A. F., de Souza, S. L. B., da Silva, V. L., de Campos, L. P., Okoshi, K., Padovani, C. R., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076201 · Cited by 31 · see citing works

Tissue Factor, Thrombosis, and Chronic Kidney Disease

Oe, Y., & Takahashi, N. (2022) · Biomedicines · doi:10.3390/biomedicines10112737 · Cited by 30 · see citing works

A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease

Chen, J., Shou, X., Xu, Y., Jin, L., Zhu, C., Ye, X., Mei, Z., & Chen, P. (2023) · Aging · doi:10.18632/aging.204611 · Cited by 30 · see citing works

A Hypoxia-Inducible Factor Stabilizer Improves Hematopoiesis and Iron Metabolism Early after Administration to Treat Anemia in Hemodialysis Patients

Ogawa, C., Tsuchiya, K., Tomosugi, N., & Maeda, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197153 · Cited by 29 · see citing works

The Hepcidin-Anemia Axis: Pathogenesis of Anemia in Chronic Kidney Disease

Nakanishi, T., Kimura, T., & Kuragano, T. (2019) · Contributions to nephrology · doi:10.1159/000496636 · Cited by 28 · see citing works

Treatment of Anemia in Kidney Disease: Beyond Erythropoietin

Wish, J. B. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.05.028 · Cited by 27 · see citing works

The oxoglutarate receptor 1 (OXGR1) modulates pressure overload-induced cardiac hypertrophy in mice

Omede, A., Zi, M., Prehar, S., Maqsood, A. R., Stafford, N., Mamas, M. A., Cartwright, E. J., & Oceandy, D. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.147 · Cited by 26 · see citing works

Drugs activating hypoxia-inducible factors correct erythropoiesis and hepcidin levels via renal EPO induction in mice

Nakai, T., Iwamura, Y., Kato, K., Hirano, I., Matsumoto, Y., Tomioka, Y., Yamamoto, M. P., & Suzuki, N. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009798 · Cited by 25 · see citing works

A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7

Cui, X., Skretting, G., Tinholt, M., Stavik, B., Dahm, A. E. A., Sahlberg, K. K., Kanse, S. M., Iversen, N., & Sandset, P. M. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.07.013 · Cited by 24 · see citing works

Hypoxia induces the dysfunction of human endothelial colony-forming cells via HIF-1α signaling

He, M., Ma, S., Cai, Q., Wu, Y. H., Shao, C.-J., Kong, H., Wang, H., Zeng, X., & Xie, W. (2017) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2017.09.013 · Cited by 22 · see citing works

Elevation of Intracellular Alpha-Ketoglutarate Levels Inhibits Osteoclastogenesis by Suppressing the NF-κB Signaling Pathway in a PHD1-Dependent Manner

Tian, J., Bao, X., Yang, F., Tang, X., Jiang, Q., Li, Y., Kang, Y., & Yin, Y. (2023) · Nutrients · doi:10.3390/nu15030701 · Cited by 17 · see citing works

Dietary alpha‐ketoglutarate inhibits SARS CoV‐2 infection and rescues inflamed lungs to restore O 2 saturation by inhibiting pAkt

Agarwal, S., Kaur, S., Asuru, T. R., Joshi, G., Shrimali, N. M., Singh, A., Singh, O. N., Srivastva, P., Shrivastava, T., Vrati, S., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1041 · Cited by 16 · see citing works

Inhibition of Hypoxia-Inducible Factor Prolyl-Hydroxylase Modulates Platelet Function

Gu, W., Qi, J., Zhang, S., Ding, Y., Qiao, J., & Han, Y. (2022) · Thrombosis and Haemostasis · doi:10.1055/a-1837-7797 · Cited by 12 · see citing works

Increased transferrin protects from thrombosis in Chuvash erythrocytosis

Shah, B. N., Zhang, X., Sergueeva, A., Miasnikova, G., Ganz, T., Prchal, J. T., & Gordeuk, V. R. (2023) · American Journal of Hematology · doi:10.1002/ajh.27021 · Cited by 10 · see citing works

Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review

Damarlapally, N., Thimmappa, V., Irfan, H., Sikandari, M. H., MADHU, K., Desai, A., Pavani, P., Zakir, S. J., Gupta, M., Khosa, M. M., et al. (2023) · Cureus · doi:10.7759/cureus.47430 · Cited by 8 · see citing works

Common Coagulopathies Associated With COVID-19 Patients

Gupta, V., Acharya, S., & Keerti, A. (2023) · Cureus · doi:10.7759/cureus.38067 · Cited by 6 · see citing works

Cardiovascular safety of current and emerging drugs to treat anaemia in chronic kidney disease: a safety review

Locatelli, F., Paoletti, E., & Vecchio, L. D. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2285889 · Cited by 5 · see citing works

Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?

Doggrell, S. A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2060078 · Cited by 3 · see citing works

The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia

TANAKA, M., Ikuma, M., Asakura, W., & Fujiwara, Y. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2275 · Cited by 1 · see citing works

Potential Roles of Hypoxia-Inducible Factor-1 in Alzheimer’s Disease: Beneficial or Detrimental?

Lin, T., Huang, C.-R., Lin, K.-J., Hsieh, Y.-H., Chen, S., Lin, Y., Chao, A., & Yang, D. (2024) · Antioxidants · doi:10.3390/antiox13111378 · Cited by 28 · see citing works

Anemia of Inflammation

Lanser, L., & Weiß, G. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-92033-2_13 · Cited by 21 · see citing works

Testosterone therapy-induced erythrocytosis: can phlebotomy be justified?

Bond, P., Verdegaal, T. J., & Smit, D. L. (2024) · Endocrine Connections · doi:10.1530/ec-24-0283 · Cited by 15 · see citing works

Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia

Joharapurkar, A. A., Pandya, V. B., Patel, H., Jain, M., & Desai, R. C. (2024) · Frontiers in Nephrology · doi:10.3389/fneph.2024.1459425 · Cited by 14 · see citing works

Annual Banned‐Substance Review 17th Edition—Analytical Approaches in Human Sports Drug Testing 2023/2024

Thevis, M., Kuuranne, T., & Geyer, H. (2024) · Drug Testing and Analysis · doi:10.1002/dta.3835 · Cited by 14 · see citing works

Zinc Deficiency in Chronic Kidney Disease and Hemodialysis: Insights from Basic Research to Clinical Implications

Nakatani, S., Morioka, T., Morioka, F., Mori, K., & Emoto, M. (2025) · Nutrients · doi:10.3390/nu17132191 · Cited by 15 · see citing works

Metabolic Pathways Affected in Patients Undergoing Hemodialysis and Their Relationship with Inflammation

Peris‐Fernández, M., Roca, M., Amengual, J. L., Balaguer-Timor, Á., Viejo-Boyano, I., Soldevila-Orient, A., Devesa-Such, R. J., Pérez, P. S., & Jaras, J. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179364 · Cited by 12 · see citing works

Derivatives of the Clinically Used HIF Prolyl Hydroxylase Inhibitor Desidustat Are Efficient Inhibitors of Human γ-Butyrobetaine Hydroxylase

Corner, T. P., Tumber, A., Salah, E., Jabbary, M., Nakashima, Y., Schnaubelt, L. I., Basak, S., Alshref, F. M., Brewitz, L., & Schofield, C. J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00586 · Cited by 10 · see citing works

Novel and Cost-Effective Manufacturing Process Development of Daprodustat

Manda, A., Basu, D., Reddy, P. S., Muttabattula, P., Komati, S. K., Nair, R., Senadi, G. C., Maruthapillai, A., & Bandichhor, R. (2025) · Organic Process Research & Development · doi:10.1021/acs.oprd.5c00041 · Cited by 9 · see citing works

Renal anemia: from relative insufficiency of EPO to imbalance of erythropoiesis and eryptosis

Yuan, M., Chen, X., Ou, R., Luo, R., Fan, W., Wang, X., & Guo, Z. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04146-x · Cited by 8 · see citing works

Lifting the veil on tumor metabolism: A GDH1-focused perspective

Zhou, S., Wu, H., Chen, Y., Lv, J., Chen, S., Yu, H., Shi, T., Wang, X., & Xiao, L. (2025) · iScience · doi:10.1016/j.isci.2025.112551 · Cited by 8 · see citing works

Network meta-analysis of HIF-prolyl hydroxylase inhibitors for anemia in dialysis-dependent and non-dialysis CKD: effects on hemoglobin, iron markers, and adverse clinical outcomes

Nasiri, H., Mirmazhari, A., Mirzakhani, L., Asgarian, P., Gholibeigi, A., Ghandali, T., Moghaddam, M. T., Mohammadi, M., Karimi, M., & Makhlough, A. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04561-x · Cited by 8 · see citing works

Profiling Inhibitor Scaffolds for the Cancer Target Jumonji‐C Domain‐Containing Protein 6

Corner, T. P., Salah, E., Tumber, A., Holt‐Martyn, J. P., Brewitz, L., & Schofield, C. J. (2025) · ChemMedChem · doi:10.1002/cmdc.202500682 · Cited by 6 · see citing works

HIF-PHIs associated with embolic and thrombotic events: a real-world pharmacovigilance study based on the Japan Adverse Drug Event Report database

Wu, D., Jiao, S., Lin, H., Xie, P., Cai, G., & Lin, M. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2491655 · Cited by 4 · see citing works

HIF inhibition: Current strategies and clinical challenges

Więch-Walów, A., Bartoszewska, S., Barton, A., Czechowicz, P., Dudzik, J., Wielockx, B., Collawn, J. F., & Bartoszewski, R. (2026) · Redox biology · doi:10.1016/j.redox.2026.104220 · Cited by 3 · see citing works

Comparative effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on prognosis in non-dialysis chronic kidney disease: a propensity-matched cohort study

Hou, Y., Wu, C., Tseng, W.-C., Wang, J., Lu, K., Zheng, C., Liu, J., Kuo, K., & Tarng, D. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2592442 · Cited by 2 · see citing works

Pharmacological HIF activation protects against diet-induced obesity, glucose intolerance, and skeletal dysfunction by exerting dual beneficial effects on energy metabolism and bone

Valle-Tenney, R., Peredo, N., Samblancx, K. D., Nefyodova, E., Cardoen, R., Dehaemers, T., Farlay, D., Chapurlat, R. D., der Schueren, B. V., Mathieu, C., et al. (2026) · Bone Research · doi:10.1038/s41413-025-00503-3 · Cited by 2 · see citing works

Testosterone-induced erythrocytosis in transgender males: Challenges arising from an increasing prevalence of metabolic syndrome and wider therapeutic indications for prescribing SGLT2 inhibitor drugs

Mohammed, A., Mamoojee, Y. H., & Quinton, R. (2024) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2024.101930 · Cited by 2 · see citing works

Recent advance of hypoxia-inducible factor prolyl hydroxylases inhibitors for anemia therapy

Wang, D., Zhao, W., Wang, Y., Ni, S., Feng, C., & Yao, S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117907 · Cited by 2 · see citing works

Global research trends in renal anemia: a multidimensional bibliometric study

Niu, Y., Wang, Y., Huo, C., & Fang, Y. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2580457 · Cited by 1 · see citing works

EGLN1 (PHD2) role in tumor microenvironment: insights for therapeutic targeting

Verna, G., Fantini, V., Grieco, A., Ciarrocchi, A., & Sancisi, V. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01602-1 · Cited by 1 · see citing works

Navigating Anemia in Solid and Hematologic Malignancies: A Comprehensive Review of Classical and Emerging Therapies

Bailey, L. K., Mahjoub, H., Lavasseur, C. M., Berkowitz, J. M., Torere, B. E., Seifer, L. V., Malhotra, A. K., & Shatzel, J. J. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70135 · Cited by 1 · see citing works

HIF-mediated hierarchical hypoxic adaptation, a novel paradigm in heart failure pathogenesis: is there a role for targeted therapies?

Yongjie, L., Jingjing, W., Yimeng, S., Aolong, W., Rui, Y., Jianru, W., Bin, L., Wang, Y., Wang, X., & Zhu, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1771529 · Cited by 1 · see citing works

Clinically approved HIF-PHIs modulate redox metabolism, cell growth, and angiogenesis independent of HIF-1α/HIF-2α

Mennerich, D., Khoder‐Agha, F., Beter, M., Dimova, E. Y., Ylä-Herttuala, S., & Kietzmann, T. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104206 · Cited by 1 · see citing works

Impact of HIF-prolyl hydroxylase inhibitors on VEGF expression and vascular adverse events in chronic kidney disease: a meta-analysis of 34 randomized controlled trials

Montazer, S. M., Asadi, A., Taghipour, A., Rajabi, A., Shabanian, A., Daraei, M., Bahmani, A., Bay, M. J., & Karimi, M. (2026) · Journal of Nephrology · doi:10.1093/joneph/aajag065 · Cited by 1 · see citing works

Drug Development in Pediatric Chronic Kidney Disease: A Review of Promising Treatments, Old Challenges, and New Strategies

Kula, A. J. (2025) · Pediatric Drugs · doi:10.1007/s40272-025-00684-8 · Cited by 1 · see citing works

Field direction of static magnetic fields influences kidney fibrosis progression through MAPK signaling and cell cycle alteration

Lee, S. M., Lee, S., Kim, K. H., Kim, D., Park, S. J., Kim, K. H., Lee, S., Bae, E., Yoo, K. D., Lee, J. W., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-09077-w · Cited by 1 · see citing works

A novel multiplex RNAi therapy simultaneously targets Hif1a and Hif2a to defy retinal degeneration in two models of AMD

Ebner, L. J. A., Imsand, C., Karademir, D., Peters, F., Kiessling, E., Fottner, A., Matter, C., Fajardo, D. S., Merolla, L., Wögenstein, G. M., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.044 · Cited by 1 · see citing works

Energy cost savings

Manley, K. (2001) · QUT ePrints (Queensland University of Technology)

Anemia in Chronic Hemodialysis at the Fousseyni Daou Hospital in Kaye, Mali: Management Challenges

Fofana, A. S., Samaké, M., Sy, S., Coulibaly, M., Djiguiba, Y. S. O., Konaré, S., Diakité, N., Tounkara, P., SIDIBE, M., Maiga, D., et al. (2025) · Open Journal of Nephrology · doi:10.4236/ojneph.2025.154052

Thrombosed epic mitral bioprosthesis in the late postoperative period: A case report

Kuwano, A., & Sato, H. (2026) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2026.01.007

Synthetic Strategies for Dustats: Comprehensive Review of Contemporary Methodological Approaches

Kunta, K. S., & Godumala, M. (2026) · Synthesis · doi:10.1055/a-2831-0436

Evidence–practice gaps in chronic kidney disease management among patients taking antidiabetic or antihypertensive medications: a nationwide analysis of Japanese primary care electronic health records

Imaizumi, T., Asada, S., Ono, H., Kanai, S., & Araki, S.-I. (2026) · Clinical and Experimental Nephrology · doi:10.1007/s10157-026-02851-8

Characterization of Novel Metabolites of the HIF Stabilizer JNJ‐42041935 in Rats Using LC‐HRMS for Doping Control Purposes: A Pilot Study

Hou, J., & Yang, S. (2026) · Drug Testing and Analysis · doi:10.1002/dta.70086

Association of nutritional indices with hyporesponsiveness to hypoxia-inducible factor-prolyl hydroxylase inhibitors in patients with chronic kidney disease: a single-center retrospective observational study

Minamishima, T., Mizoguchi, H., Nishibori, N., & Ikesue, H. (2026) · BMC Nephrology · doi:10.1186/s12882-026-05074-x

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: Mechanisms, Therapeutic Applications, and Developmental Progress

Fangyu, Y., & Shuangquan, K. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101472

Role of Hypoxia-Inducible Factor–1α in Regulating Muscle Degeneration After Rotator Cuff Tears

Zhang, H., Lee, A., Liu, M., Diaz, A., Zhang, Y., Kim, H. T., Feeley, B. T., & Liu, X. (2026) · The American Journal of Sports Medicine · doi:10.1177/03635465261469689

The pathological mechanisms and potential therapeutic strategies for renal anemia

Rao, J.-X., Zhou, H.-M., Leu, K. F., Liu, M., Liu, Z.-F., & Tang, Y.-P. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1847564

BindingDB Entry 50023353: Derivatives of the Clinically Used HIF Prolyl Hydroxylase Inhibitor Desidustat Are Efficient Inhibitors of Human γ-Butyrobetaine Hydroxylase.

BindingDB (2026) · UC San Diego · doi:10.7270/q2tq66gb

[Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].

Maruno, S., Tanaka, T., & Nangaku, M. (2021) · PubMed · doi:10.11406/rinketsu.62.371 · Cited by 1 · see citing works

Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease

Haase, V. H. (2021) · Kidney International Supplements · doi:10.1016/j.kisu.2020.12.002 · Cited by 203 · see citing works

Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease

Kurata, Y., Tanaka, T., & Nangaku, M. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000617 · Cited by 26 · see citing works

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease

Bartnicki, P. (2024) · Biomedicines · doi:10.3390/biomedicines12081884 · Cited by 18 · see citing works

[Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors].

Nangaku, M. (2021) · PubMed · doi:10.11406/rinketsu.62.938